Salute e Benessere

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for…

®editing process in hematopoietic stem and progenitor cells (HSPCs) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 27 thAnnual Meeting, to be held in Baltimore, Maryland, on May 7-11, 2024. Poster presentations: Title: Circularization of Non-Viral Single-Strand DNA Template for Gene Correction and Gene Insertion Improves Editing Outcomes in HSPCsPresenter : Alex Boyne, Gene Editing Platform Manager at CellectisSession Date/Time:May 9, 2024 at 12PM...
Nasdaq GlobeNewswire
08/04/2024

Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5%…

Download Sample Report: https://www.alliedmarketresearch.com/request-sample/A220683 Download Sample Report:https://www.alliedmarketresearch.com/request-sample/A220683 Prime Determinants of Growth The growth of the caffeine powder market is primarily driven by increasing popularity of sports and fitness supplements. Athletes and fitness enthusiasts rely on caffeine as a performance enhancer to improve endurance, alleviate fatigue, and optimize physical performance. Consequently,...
PR Newswire
08/04/2024

Transparency Notifications from Shareholders

PRESS RELEASE REGULATED INFORMATION8 April 2024, 06:30 pm CEST Ghent, Belgium – 8 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received transparency notifications from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the table…
Nasdaq GlobeNewswire
08/04/2024

EssilorLuxottica: First-Quarter 2024 Revenue Conference Call Invitation

First-Quarter 2024 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations,have the pleasure of inviting you to our First-Quarter 2024 Revenue Conference Call on: Thursday, April 18, 2024, at 6:30 pm CEST Dial-in telephone access:If you wish to dial into the conference call, please pre-register at the following link to receive the personal credentials (Dial-in numbers, Conference ID and User ID):https://aiti...
Nasdaq GlobeNewswire
08/04/2024

Ipsen - Monthly information relative to the total number of voting rights and…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)31 March 202483,814,526Gross...
Nasdaq GlobeNewswire
08/04/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of March 31, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (April 8, 2024 - 6:00 pm)– As of March 31, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks...
Nasdaq GlobeNewswire
08/04/2024

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

COMBINED GENERAL MEETING OF APRIL 30, 2024AVAILABILITY OF PREPARATORY DOCUMENTS The Company's shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris.The notice of meeting ( avis de réunion ), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was...
Nasdaq GlobeNewswire
08/04/2024

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of…

Market Dynamics: Market Dynamics: The growth of the elbow replacement market can be attributed to the increasing incidence of elbow injuries due to sports activities, trauma, and aging population. In addition, advancements in technology leading to the development of innovative elbow replacement devices are further driving market growth. Global Elbow Replacement Market Report Coverage • The growing prevalence of osteoarthritis • The increasing demand for minimally invasive...
PR Newswire
08/04/2024

United States Container Glass Market to Reach US$ 14.59 Billion by 2031, Rising…

The United States Container Glass Market is being primarily driven by the increasing adoption of sustainable packaging solutions. Consumers are becoming more conscious about the environmental impact of their choices, leading to a growing demand for eco-friendly packaging materials such as container glass. Additionally, the durability and recyclability of container glass further contribute to its popularity in various industries. The United States Container Glass Market is being primarily…
PR Newswire
08/04/2024

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says…

Market Dynamics: Market Dynamics: The Urethral Dilators Market is driven by the increasing prevalence of urethral strictures, which is leading to a growing demand for minimally invasive treatment options such as urethral dilators. Additionally, technological advancements in urethral dilators are also contributing to market growth by providing safer and more effective treatment options for patients. Global Urethral Dilators Market Report Coverage • Increasing prevalence of chronic...
PR Newswire
08/04/2024

Sepsis Diagnostics Market Worth $890 million | MarketsandMarkets™.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155 Browse in-depth TOC on "Sepsis Diagnostics Market" 167 - Tables 18 - Figures 266 - Pages Sepsis Diagnostics Market Scope: The molecular diagnostics segment is to register a significant growth rate over the forecast period of 2024-2029. Based on the technology,...
PR Newswire
08/04/2024

The first press conference with cats was held in Colombia

The campaign is based on the concept of empowered self-care and combines Sanofi's social commitment with a positive impact on the lives of people and their pets. The campaign is supported by a series of decisive scientific findings: humans are allergic to the Fel d1 protein, which is produced in the sebaceous glands and skin of felines and transmitted to their fur and dander during grooming. It has been proven that when cats are spayed, the production of this allergen is reduced by 90%. The...
PR Newswire
08/04/2024

Bulat Utemuratov Foundation supports World Autism Awareness Day with initiatives…

Over the month of April, the Foundation's Asyl Miras Autism Centers, which operate in 12 cities acrossKazakhstan, will hold open days to educate visitors about ASD. Activities will include site tours for those who want to learn about ASD, including regional state officials, activists, and others. Additionally, there will be practical seminars for parents, teachers and specialists across the health, social welfare, and education sectors. Marat Aitmagambetov, Director of the Bulat...
PR Newswire
08/04/2024

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 08 April 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a…
Nasdaq GlobeNewswire
08/04/2024

Invitation to the annual shareholders' meeting

The annual shareholders' meeting will be held onTuesday April 30, 2024 at 4:00 pm CET at Bella Center, Center Boulevard 5, Denmark.The distribution of profit will be addressed at the meeting and the Board of Directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 - December 31) of 2023. This equals a pay-out ratio of 53.2% of Novonesis' adjusted net profit for the four-month period.Following the approval of the proposed...
Nasdaq GlobeNewswire
08/04/2024

StickIt Technologies Inc. Announces Year-End 2023 Financial Results

Notes: 1. All the revenues have been generated by selling the licenses for the distribution of Extra-C stick. 2. The increase in the operational expenses was primarily attributable to the professional fees as well as the additional services hike associated with the transaction costs of the RTO and the listing with the CSE. Most of these fees were one-time costs. 3. During 2023 the Company incurred losses ofCAD$48,986,000of whichCAD$47,695,000resulted from...
PR Newswire
08/04/2024

Clario appoints Julia James as Chief Legal and Administrative Officer

"We are excited to welcome Julia James to Clario," said Chris Fikry, M.D., Chief Executive Officer at Clario. "Her extensive legal and compliance expertise will help us continue to advance Clario's impact in clinical trials, further enhancing our efforts on quality and speed to empower our partners to transform lives." "We are excited to welcomeJulia Jamesto Clario," said Chris Fikry, M.D., Chief Executive Officer at Clario."Her extensive legal and compliance…
PR Newswire
08/04/2024

Endo, Inc. Announces Proposed Private Offering of Senior Secured Notes

The offering constitutes part of the exit financing required under the Fourth Amended Joint Chapter 11 Plan of Reorganization of Endo International plc ("EIP") and its affiliated debtors (the "Plan"). Endo expects its initial capital structure to consist of a $400.0 million senior secured five-year super-priority revolving credit facility (undrawn at emergence), a $1,250.0 million senior secured seven-year term loan and the $1,250.0 million aggregate principal amount of the…
PR Newswire
08/04/2024

Seegene and UK Health Security Agency convene a summit to collectively realize…

Prof. Harries expressed keen interest in Seegene's SG OneSystemTM business, the company's technology sharing initiative, as well as its advancements in automated diagnostic reagent development system driven by artificial intelligence (AI) and innovative digital solutions that integrate biotechnology (BT) and information technology (IT). Prof. Harries expressed keen interest in Seegene's SG OneSystem TMbusiness, the company's technology sharing initiative, as well as its advancements in...
PR Newswire
08/04/2024

American College of Cardiology Presentation Highlights Promising Results Showing…

Pre-drug and post-drug monitoring of coronary artery inflammation and fatal heart attack risk in the trial was accomplished using the CaRi-Heart® AI technology fromCaristo Diagnostics, a leading cardiac disease diagnostics company. The trial results are concurrently published in Cardiovascular Research . Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease...
PR Newswire
08/04/2024

Theriva™ Biologics Announces Presentation at the American Society for Cell and…

thAnnual Meeting, being held both virtually and in Baltimore from May 7-11, 2024. “We look forward to presenting data at the upcoming ASGCT meeting that further highlight the potential of our systemically administered oncolytic adenovirus, VCN-01, to synergistically combine with an expanding range of standard-of-care chemotherapies for difficult-to-treat cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “ Our on-going VIRAGE Phase 2b trial is evaluating...
Nasdaq GlobeNewswire
08/04/2024

European Association of Urology (EAU) 2024 congress features new data on modern…

In addition to this educational activity, the EAU scientific program prominently features Photocure's Hexvix® product and/or the blue light cystoscopy procedure in which it is used. In particular, two notable abstract presentations were: In addition to this educational activity, the EAU scientific program prominently features Photocure's Hexvix ®product and/or the blue light cystoscopy procedure in which it is used. In particular, two notable abstract presentations were: Outpatient laser...
PR Newswire
08/04/2024

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine…

According to Dr. Kahn, "The study results, which include data from patients who received up to four years of treatment on LYBALVI, demonstrated that the combination of olanzapine and samidorphan delivered long-term tolerability, including across key weight and metabolic parameters, and sustained symptom control, further reinforcing LYBALVI's potential utility as a foundational maintenance treatment option for people living with schizophrenia or bipolar I disorder." According to Dr…
PR Newswire
08/04/2024

Global Antibody Discovery Market Valuation Set to Total US$ 21.8 Billion by…

Phage display remains the most widely used antibody discovery method owing to its versatility, robustness, applicability, and other advantages. The target segment is anticipated to thrive at 9.7% CAGR through 2034. Phage display remains the most widely used antibody discovery method owing to its versatility, robustness, applicability, and other advantages. The target segment is anticipated to thrive at9.7% CAGRthrough 2034. Download the Sample PDF report to explore key market insights...
PR Newswire
08/04/2024
Altri  Comunicati